Rethinking hemocompatibility standards: a critical appraisal of current regulatory frameworks for Advanced Therapy Medicinal Products (ATMPs) validation
Acta Biomaterialia · 2026-09 · 222 · 156-172
DOI: 10.1016/j.actbio.2026.08.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2026-09. Verfasst von Hachem Bouarroudj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Science, University of Namur, 5000 Namur, Belgium. Hauptthemen laut MEDLINE: Materials Testing. Die Arbeit nennt 65 Literaturangaben. Gefördert von: Waalse Gewest, Walloon Region.
Abstract (Originalsprache)
Hemocompatibility, defined as the ability of a product to interact safely with blood components, is a critical requirement for therapies intended for intravascular administration. Current evaluation frameworks, primarily based on ISO 10993-4:2017, were initially developed for inert medical devices and rely on static assays assessing hemolysis, coagulation, platelet activation, and complement activation. However, these approaches remain limited when applied to Advanced Therapy Medicinal Products (ATMPs), which are dynamic and biologically active. Unlike conventional devices, ATMPs interact continuously with immune and hemostatic systems under flow conditions. Existing methodologies do not fully capture shear-dependent and time-evolving thrombo-inflammatory processes, may show variability, and have limited translational relevance. In addition, innate immune activation, an important contributor to ATMP-related adverse events, is not sufficiently considered. Regulatory guidance from major agencies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), remains indirect, leading to variability in practices and uncertainty in study design and interpretation. This review critically examines current hemocompatibility assessment strategies for ATMPs and highlights the need for adapted frameworks. It proposes redefining hemocompatibility as controlled blood-interaction and supports the integration of dynamic flow-based models and mechanistic assays within a risk-based, tiered approach to improve predictivity, standardization, and safety. Such an evolution is essential to implement more biologically relevant and clinically meaningful hemocompatibility standards for ATMPs. STATEMENT OF SIGNIFICANCE: Current hemocompatibility standards were primarily designed for inert medical devices and do not adequately address the biological complexity of advanced therapy medicinal products (ATMPs), such as cell and gene therapies. This review highlights important scientific and regulatory gaps in existing testing frameworks, particularly regarding thrombo-inflammatory and immune-mediated blood interactions. By analyzing current limitations and emerging technologies, including dynamic flow-based and microphysiological models, this work proposes a shift from the traditional concept of blood inertness toward controlled blood interaction. This perspective may help improve the predictive value of preclinical safety testing and support the development of more appropriate regulatory standards for next-generation advanced therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Science, University of Namur, 5000 Namur, Belgium.
- ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium; Department of Endocrinology, ULB Erasmus Hospital, Brussels University Hospital, Université Libre de Bruxelles, Brussels, Belgium; WEL…
- Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium; ULB Center for Research in Immunology (U-CRI), Gosselies, Belgium.
- Laboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical Research, UCLouvain, Brussels, Belgium.
- Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Science, University of Namur, 5000 Namur, Belgium; Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Fer…
Förderung
- Waalse Gewest
- Walloon Region
Zitieren
APA
Bouarroudj, H., Gillot, C., Cnop, M., Dogné, J. M., Flamand, V., Leclercq, I., Michaux, P., & Douxfils, J. (2026). Rethinking hemocompatibility standards: a critical appraisal of current regulatory frameworks for Advanced Therapy Medicinal Products (ATMPs) validation. Acta Biomaterialia, 222, 156-172. https://doi.org/10.1016/j.actbio.2026.08.003
Vancouver
Bouarroudj H, Gillot C, Cnop M, Dogné JM, Flamand V, Leclercq I, et al. Rethinking hemocompatibility standards: a critical appraisal of current regulatory frameworks for Advanced Therapy Medicinal Products (ATMPs) validation. Acta Biomaterialia. 2026;222:156-172. doi:10.1016/j.actbio.2026.08.003
BibTeX
@article{Bouarroudj2026,
author = {Bouarroudj, Hachem and Gillot, Constant and Cnop, Miriam and Dogné, Jean-Michel and Flamand, Véronique and Leclercq, Isabelle and Michaux, Pauline and Douxfils, Jonathan},
title = {Rethinking hemocompatibility standards: a critical appraisal of current regulatory frameworks for Advanced Therapy Medicinal Products (ATMPs) validation},
journal = {Acta Biomaterialia},
year = {2026},
volume = {222},
pages = {156--172},
doi = {10.1016/j.actbio.2026.08.003}
}
EUVIMED